W Löscher

2.3k total citations
43 papers, 1.9k citations indexed

About

W Löscher is a scholar working on Psychiatry and Mental health, Pediatrics, Perinatology and Child Health and Cellular and Molecular Neuroscience. According to data from OpenAlex, W Löscher has authored 43 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Psychiatry and Mental health, 26 papers in Pediatrics, Perinatology and Child Health and 22 papers in Cellular and Molecular Neuroscience. Recurrent topics in W Löscher's work include Epilepsy research and treatment (27 papers), Pharmacological Effects and Toxicity Studies (26 papers) and Neuroscience and Neuropharmacology Research (21 papers). W Löscher is often cited by papers focused on Epilepsy research and treatment (27 papers), Pharmacological Effects and Toxicity Studies (26 papers) and Neuroscience and Neuropharmacology Research (21 papers). W Löscher collaborates with scholars based in Germany, Austria and United States. W Löscher's co-authors include Dagmar Hönack, Heinz Nau, H.‐H. Frey, H. Nau, H Frey, Chris Rundfeldt, Christian Brandt, Minxuan Sun, Curtis R. Brandt and Alexandra M. Gastens and has published in prestigious journals such as Journal of Neuroscience, Brain Research and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

W Löscher

43 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
W Löscher Germany 25 1.1k 945 773 516 184 43 1.9k
Denson G. Fujikawa United States 24 1.5k 1.4× 925 1.0× 565 0.7× 897 1.7× 102 0.6× 42 2.5k
Dagmar Hönack Germany 30 2.3k 2.1× 1.5k 1.6× 954 1.2× 1.0k 2.0× 159 0.9× 48 3.1k
Wolfgang Löscher Germany 23 1.4k 1.2× 937 1.0× 566 0.7× 563 1.1× 95 0.5× 32 2.3k
L. M. Ojemann United States 26 585 0.5× 1.2k 1.3× 791 1.0× 185 0.4× 102 0.6× 38 1.7k
Misty D. Smith United States 22 848 0.8× 600 0.6× 307 0.4× 521 1.0× 71 0.4× 40 1.5k
Wolfgang Löscher Germany 12 540 0.5× 440 0.5× 349 0.5× 277 0.5× 39 0.2× 12 966
P.E. Keane France 20 748 0.7× 257 0.3× 253 0.3× 459 0.9× 55 0.3× 41 1.4k
Elsa M. Valdizán Spain 25 867 0.8× 474 0.5× 295 0.4× 366 0.7× 108 0.6× 57 1.8k
Melissa Barker‐Haliski United States 18 867 0.8× 641 0.7× 244 0.3× 358 0.7× 60 0.3× 52 1.3k
Brian D. Klein United States 18 703 0.6× 538 0.6× 254 0.3× 498 1.0× 45 0.2× 26 1.2k

Countries citing papers authored by W Löscher

Since Specialization
Citations

This map shows the geographic impact of W Löscher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W Löscher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W Löscher more than expected).

Fields of papers citing papers by W Löscher

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W Löscher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W Löscher. The network helps show where W Löscher may publish in the future.

Co-authorship network of co-authors of W Löscher

This figure shows the co-authorship network connecting the top 25 collaborators of W Löscher. A scholar is included among the top collaborators of W Löscher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W Löscher. W Löscher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Brandt, Christian, et al.. (2010). Disease-Modifying Effects of Phenobarbital and the NKCC1 Inhibitor Bumetanide in the Pilocarpine Model of Temporal Lobe Epilepsy. Journal of Neuroscience. 30(25). 8602–8612. 148 indexed citations
2.
Schirmer, Michael, et al.. (2007). Marked differences in response to dopamine receptor antagonism in two rat mutants, ci2 and ci3, with lateralized rotational behavior. Behavioural Brain Research. 180(2). 218–225. 16 indexed citations
3.
Brandt, Curtis R., et al.. (2006). Treatment with valproate after status epilepticus: Effect on neuronal damage, epileptogenesis, and behavioral alterations in rats. Neuropharmacology. 51(4). 789–804. 124 indexed citations
4.
Löscher, W & Ilo E. Leppik. (2002). Critical re-evaluation of previous preclinical strategies for the discovery and the development of new antiepileptic drugs. Epilepsy Research. 50(1-2). 17–20. 19 indexed citations
5.
Löscher, W & Dagmar Hönack. (2000). Development of Tolerance During Chronic Treatment of Kindled Rats With the Novel Antiepileptic Drug Levetiracetam. Epilepsia. 41(12). 1499–1506. 41 indexed citations
6.
Rundfeldt, Chris, Piotr Właź, Dagmar Hönack, & W Löscher. (1995). Anticonvulsant tolerance and withdrawal characteristics of benzodiazepine receptor ligands in different seizure models in mice. Comparison of diazepam, bretazenil and abecarnil.. Journal of Pharmacology and Experimental Therapeutics. 275(2). 693–702. 47 indexed citations
7.
Turski, L., David Stephens, Leif H. Jensen, et al.. (1990). Anticonvulsant action of the beta-carboline abecarnil: studies in rodents and baboon, Papio papio.. Journal of Pharmacology and Experimental Therapeutics. 253(1). 344–352. 74 indexed citations
8.
Löscher, W, et al.. (1990). [Flumazenil (Anexate): pharmacodynamics, pharmacokinetics, indications and contraindications].. PubMed. 85(3). 156–62, 169. 2 indexed citations
9.
Löscher, W. (1989). Valproate enhances GABA turnover in the substantia nigra. Brain Research. 501(1). 198–203. 68 indexed citations
10.
Löscher, W, J. Edward Fisher, H. Nau, & Dagmar Hönack. (1989). Valproic acid in amygdala-kindled rats: alterations in anticonvulsant efficacy, adverse effects and drug and metabolite levels in various brain regions during chronic treatment.. Journal of Pharmacology and Experimental Therapeutics. 250(3). 1067–1078. 58 indexed citations
11.
12.
Löscher, W, et al.. (1983). High anticonvulsant potency of gamma-aminobutyric acid (GABA)mimetic drugs in gerbils with genetically determined epilepsy.. Journal of Pharmacology and Experimental Therapeutics. 226(3). 839–844. 30 indexed citations
13.
Schwartz-Porsche, D, W Löscher, & H.‐H. Frey. (1982). Treatment of canine epilepsy with primidone. Journal of the American Veterinary Medical Association. 181(6). 592–595. 17 indexed citations
14.
Löscher, W. (1982). Cardiovascular effects of GABA, GABA-aminotransferase inhibitors and valproic acid following systemic administration in rats, cats and dogs: pharmacological approach to localize the site of action.. PubMed. 257(1). 32–58. 28 indexed citations
15.
Löscher, W. (1981). Anticonvulsant activity of metabolites of valproic acid.. PubMed. 249(1). 158–63. 36 indexed citations
16.
Frey, H.‐H. & W Löscher. (1980). Clinical Pharmacokinetics of Phenytoin in the Dog: A Reevaluation. American Journal of Veterinary Research. 41(10). 1635–1638. 23 indexed citations
17.
Frey, H.‐H. & W Löscher. (1980). Pharmacokinetics of carbamazepine in the dog.. PubMed. 243(2). 180–91. 29 indexed citations
18.
Frey, H.‐H., et al.. (1979). Pharmacokinetics of primidone and its active metabolites in the dog.. PubMed. 242(1). 14–30. 34 indexed citations
19.
Löscher, W. (1978). Serum protein binding and pharmacokinetics of valproate in man, dog, rat and mouse.. Journal of Pharmacology and Experimental Therapeutics. 204(2). 255–261. 114 indexed citations
20.
Löscher, W, et al.. (1976). Di-n-propylacetic acid--profile of anticonvulsant activity in mice.. PubMed. 26(2). 299–301. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Denson G. Fujikawa Breakdown of academic impact, for papers by Dagmar Hönack Breakdown of academic impact, for papers by Wolfgang Löscher Breakdown of academic impact, for papers by L. M. Ojemann Breakdown of academic impact, for papers by Misty D. Smith Breakdown of academic impact, for papers by Wolfgang Löscher Breakdown of academic impact, for papers by P.E. Keane Breakdown of academic impact, for papers by Elsa M. Valdizán Breakdown of academic impact, for papers by Melissa Barker‐Haliski Breakdown of academic impact, for papers by Brian D. Klein
Rankless by CCL
2026